



Caribou Biosciences to Present at Upcoming Investor Conferences

October 20, 2021

BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](https://www.cariboubio.com) (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's President and Chief Executive Officer, will present a company overview at the following upcoming investor conferences.

- Jefferies Gene Therapy/Editing Summit: Wednesday, October 27, 1:00-1:25 PM ET
- Barclays Gene Editing & Gene Therapy Summit: Monday, November 15, 9:30-9:55 AM ET

Live webcasts of the presentations will be accessible via Caribou's website on the [Events](#) page. Archived copies of the webcasts will be available on the Caribou website for 30 days after the events.

About Caribou's Novel Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNA (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of the chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc.

Contacts:

Amy Figueroa, CFA
Investor Relations and Corporate Communications
afigueroa@cariboubio.com

Investors:

Elizabeth Wolffe, Ph.D. and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhousesa.com
swheeler@wheelhousesa.com

Media:

Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
617-461-4023